NuVasive announced it received 510(k) clearance from the U.S. FDA, as well as European CE mark approva, for use of its Precice Bone Transport System, the only all-internal system of its kind on the market indicated for use in segmental bone loss treatment in the tibia and femur resulting from trauma or infection. The Precice Bone Transport System joins the NuVasive Specialized Orthopedics family of advanced, magnetically adjustable limb-lengthening products which have collectively been used to treat thousands of patients. NSO is a division of NuVasive, focused on the design and innovation of disruptive orthopedic solutions, including its proprietary platform of magnetically adjustable implant systems. The Precice Bone Transport System is expected to launch commercially in the U.S. and Europe in third quarter 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.